[go: up one dir, main page]

WO2012115474A3 - 신규한 수두 대상포진 바이러스주 및 이를 이용한 수두 및 대상포진 바이러스 백신 - Google Patents

신규한 수두 대상포진 바이러스주 및 이를 이용한 수두 및 대상포진 바이러스 백신 Download PDF

Info

Publication number
WO2012115474A3
WO2012115474A3 PCT/KR2012/001408 KR2012001408W WO2012115474A3 WO 2012115474 A3 WO2012115474 A3 WO 2012115474A3 KR 2012001408 W KR2012001408 W KR 2012001408W WO 2012115474 A3 WO2012115474 A3 WO 2012115474A3
Authority
WO
WIPO (PCT)
Prior art keywords
zoster virus
same
chicken pox
varicella
vaccine
Prior art date
Application number
PCT/KR2012/001408
Other languages
English (en)
French (fr)
Other versions
WO2012115474A2 (ko
Inventor
김근희
권시내
이찬희
윤엽
Original Assignee
재단법인 목암생명공학연구소
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 재단법인 목암생명공학연구소 filed Critical 재단법인 목암생명공학연구소
Priority to KR1020137022427A priority Critical patent/KR20140022799A/ko
Priority to US14/000,770 priority patent/US20140147458A1/en
Priority to CN2012800103717A priority patent/CN103392001A/zh
Priority to MX2013009723A priority patent/MX2013009723A/es
Priority to BR112013027247A priority patent/BR112013027247A2/pt
Priority to EP12749337.7A priority patent/EP2679683A4/en
Priority to JP2013555367A priority patent/JP2014508522A/ja
Priority to RU2013143146/10A priority patent/RU2580003C2/ru
Publication of WO2012115474A2 publication Critical patent/WO2012115474A2/ko
Publication of WO2012115474A3 publication Critical patent/WO2012115474A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/04—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

본 발명은 신규 수두 대상포진 바이러스주 및 이를 이용한 수두 및 대상포진 바이러스 백신에 관한 것으로, 보다 상세하게는 한국인 환자로부터 분리된 VZV MVA06의 게놈 DNA 및 이의 오픈 리딩 프레임(open reading frame, 이하 'ORF'라 한다), 상기 VZV MVA06의 게놈 DNA 및 이의 ORF에 의해 코딩되는 단백질 및 상기 단백질을 유효성분으로 하는 백신 조성물에 관한 것이다.
PCT/KR2012/001408 2011-02-24 2012-02-24 신규한 수두 대상포진 바이러스주 및 이를 이용한 수두 및 대상포진 바이러스 백신 WO2012115474A2 (ko)

Priority Applications (8)

Application Number Priority Date Filing Date Title
KR1020137022427A KR20140022799A (ko) 2011-02-24 2012-02-24 신규한 수두 대상포진 바이러스주 및 이를 이용한 수두 및 대상포진 바이러스 백신
US14/000,770 US20140147458A1 (en) 2011-02-24 2012-02-24 Novel varicella-zoster virus strains, and chicken pox and herpes zoster virus vaccine using same
CN2012800103717A CN103392001A (zh) 2011-02-24 2012-02-24 新型水痘-带状疱疹病毒株以及使用所述毒株的水痘和带状疱疹病毒疫苗
MX2013009723A MX2013009723A (es) 2011-02-24 2012-02-24 Cepas del virus de varicela-zoster novedosas, y vacunas del virus del herpes zoster y varicela usando los mismos.
BR112013027247A BR112013027247A2 (pt) 2011-02-24 2012-02-24 Cepas do vírus da varicela-zóster e vacina contra o vírus da catapora e herpes zóster usando as mesmas
EP12749337.7A EP2679683A4 (en) 2011-02-24 2012-02-24 NEW VARICELLA ZOSTER VIRUSES AND WINDPOCK AND HERPES ZOSTER VIRUS VACCINE THEREOF
JP2013555367A JP2014508522A (ja) 2011-02-24 2012-02-24 新規な水痘帯状疱疹ウイルス株及びそれを用いた水痘及び帯状疱疹ウイルスワクチン
RU2013143146/10A RU2580003C2 (ru) 2011-02-24 2012-02-24 Новые штаммы вируса ветряной оспы и противовирусная вакцина против ветряной оспы и опоясывающего лишая, в которой применяются такие штаммы

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161446284P 2011-02-24 2011-02-24
US61/446,284 2011-02-24

Publications (2)

Publication Number Publication Date
WO2012115474A2 WO2012115474A2 (ko) 2012-08-30
WO2012115474A3 true WO2012115474A3 (ko) 2012-11-22

Family

ID=46721358

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/001408 WO2012115474A2 (ko) 2011-02-24 2012-02-24 신규한 수두 대상포진 바이러스주 및 이를 이용한 수두 및 대상포진 바이러스 백신

Country Status (9)

Country Link
US (1) US20140147458A1 (ko)
EP (1) EP2679683A4 (ko)
JP (1) JP2014508522A (ko)
KR (1) KR20140022799A (ko)
CN (1) CN103392001A (ko)
BR (1) BR112013027247A2 (ko)
MX (1) MX2013009723A (ko)
RU (1) RU2580003C2 (ko)
WO (1) WO2012115474A2 (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9017698B2 (en) 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
KR102416781B1 (ko) 2015-08-20 2022-07-05 고려대학교 산학협력단 수두 대상포진 바이러스에 의해 유발되는 질병의 치료 또는 예방용 약학 조성물
US10874734B2 (en) 2016-11-25 2020-12-29 Mogam Institute For Biomedical Research Varicella zoster virus vaccine
WO2018097642A1 (ko) * 2016-11-25 2018-05-31 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스 백신
EP3560512A4 (en) 2016-12-26 2020-07-22 Mogam Institute for Biomedical Research COMPOSITION OF VACCINE AGAINST ZONA
WO2019035605A2 (ko) 2017-08-16 2019-02-21 주식회사 차백신연구소 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도
KR102098097B1 (ko) 2017-08-16 2020-05-26 주식회사 차백신연구소 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도
US11642408B2 (en) * 2018-05-23 2023-05-09 Mogam Institute For Biomedical Research Antigen variant of Varicella Zoster virus and use thereof
CN115192703A (zh) * 2021-04-08 2022-10-18 长春百克生物科技股份公司 一种带状疱疹疫苗及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0135614B1 (ko) * 1994-11-23 1998-04-23 허영섭 약독화 수두 생바이러스 백신 및 그의 제조방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024616A1 (en) * 1992-06-04 1993-12-09 Merck & Co., Inc. Process for attenuated varicella zoster virus vaccine production
US7112331B2 (en) * 1996-02-09 2006-09-26 Smithkline Beecham Biologicals, S.A. Vaccines against varicella zoster virus gene 63 product
US6528066B1 (en) * 1999-09-14 2003-03-04 University Of Iowa Research Foundation Variant varicella-zoster viruses and methods of use
AU2002951692A0 (en) * 2002-09-23 2002-10-17 Vital Biotech (Hong Kong) Limited Improvements in or relating to vaccines
CN1950507A (zh) * 2004-03-05 2007-04-18 财团法人阪大微生物病研究会 重组水痘－带状疱疹病毒
AU2005338519B2 (en) * 2005-11-24 2011-06-16 National Institute Of Biomedical Innovation Recombinant polyvalent vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0135614B1 (ko) * 1994-11-23 1998-04-23 허영섭 약독화 수두 생바이러스 백신 및 그의 제조방법

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HWANG, K. K. ET AL.: "Marker test for attenuation of varicella-zoster viruses isolated in Korea", THE JOURNAL OF THE KOREAN SOCIETY OF VIROLOGY., vol. 22, no. 2, December 1992 (1992-12-01), pages 105 - 109, XP008170562 *
KIM, J. I. ET AL.: "Sequencing and characterization of Varicella-zoster virus vaccine strain SuduVax", VIROLOGY JOURNAL., vol. 8, 16 December 2011 (2011-12-16), pages 547, XP021093914 *
SOHN, Y. M. ET AL.: "''Safety and Immunogenicity of Live attenuated Varicella Virus Vaccine (MAV/06 strain)", THE JOURNAL OF KOREAN PEDIATRIC SOCIETY., vol. 37, no. 10, October 1994 (1994-10-01), pages 1405 - 1413, XP055126753 *
TILLIEUX, S. L. ET AL.: "Complete DNA sequences of two oka strain varicella-zoster virus genomes", JOURNAL OF VIROLOGY., vol. 82, no. 22, 10 September 2008 (2008-09-10), pages 11023 - 11044, XP055120262 *

Also Published As

Publication number Publication date
CN103392001A (zh) 2013-11-13
BR112013027247A2 (pt) 2017-08-22
EP2679683A4 (en) 2015-07-15
RU2580003C2 (ru) 2016-04-10
RU2013143146A (ru) 2015-03-27
WO2012115474A2 (ko) 2012-08-30
JP2014508522A (ja) 2014-04-10
KR20140022799A (ko) 2014-02-25
EP2679683A2 (en) 2014-01-01
US20140147458A1 (en) 2014-05-29
MX2013009723A (es) 2013-09-16

Similar Documents

Publication Publication Date Title
WO2012115474A3 (ko) 신규한 수두 대상포진 바이러스주 및 이를 이용한 수두 및 대상포진 바이러스 백신
WO2013110818A3 (en) Immunogens for hiv vaccination
WO2017070626A3 (en) Respiratory virus vaccines
WO2017070620A3 (en) Broad spectrum influenza virus vaccine
MX2018004918A (es) Vacuna del virus herpes simple.
EP2765138A3 (en) HIV-1 envelope glycoprotein
HK1207871A1 (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
EA201301320A1 (ru) 4-арил-n-фенил-1,3,5-триазин-2-амины, которые содержат сульфоксиминную группу
EA201690497A2 (ru) Композиции и способы ингибирования экспрессии генов вируса гепатита в
WO2012025944A3 (en) Sitagliptin, salts and polymorphs thereof
WO2012168430A3 (en) Polypeptides
EA201391495A1 (ru) Производные пиримидина для лечения вирусных инфекций
WO2013014294A3 (en) Improved baculovirus expression systems
WO2012061815A3 (en) RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs)
WO2011109511A3 (en) Novel hiv-1 envelope glycoprotein
WO2015052543A3 (en) Malaria vaccination
EP2568289A3 (en) Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
WO2009080806A3 (en) Modified influenza virus
PH12015500771A1 (en) Novel fc gamma receptor iib variants
WO2011157447A3 (en) Modified parvovirus having enhanced anti-tumour efficacy
WO2014060493A3 (en) N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group
WO2009158618A8 (en) Avian reoviridae
WO2014167582A3 (en) Vaccine composition for prophylaxis in ruminants
WO2012063115A3 (en) Process for the preparation of rosuvastatin calcium via novel amine intermediate
WO2015027137A8 (en) Improved synthesis of capuramycin and its analogues

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12749337

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013555367

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14000770

Country of ref document: US

ENP Entry into the national phase

Ref document number: 20137022427

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/009723

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1301004592

Country of ref document: TH

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2012749337

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012749337

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013143146

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013027247

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013027247

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130826